Indian drugmaker Theon Pharma gets warning letter for falsifying records, other issues

Maltese National Agency inspectors found one “critical” deficiency during an inspection conducted in early March. (EMA)

Indian drugmaker Theon Pharmaceuticals was issued a warning letter, citing the company for falsifying records and inadequate quality control systems.

The letter, posted on the EudraGMP website, said inspectors found one “critical” deficiency during an inspection conducted by the Maltese National Agency in early March.

The critical issue concerned “evidence of falsification of documents.” Six “major” deficiencies were documented, which included “inadequate pharmaceutical quality system and documentation management, and deficient control of cross-contamination, manufacturing activities, qualification and validation activities and approval of suppliers.”

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

The facility, which is located in Village Saini Majra, Tehsil Nalagarh, District Solan, Himachal Pradesh, was also cited for 11 other issues. Currently, the plant isn’t producing drugs for the European market, and the agency recommended Theon Pharma not be granted either marketing authorizations or variation applications to current marketing authorizations for the site.

Theon produces both coated and uncoated tablets at the facility, which has a capacity of making about 700 million units a year, according to the company’s website.

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Mylan is the most recent drugmaker facing the FDA's ire over a tainted API that led to a global recall of "sartan"-based drugs last year.

Merck MSD's $1.2 billion production restructuring has fallen on a site in France, where more than 200 manufacturing and R&D jobs will be swept away.